Nuvalent, Inc. — Director's Dealing 2024

Mar 29, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Nuvalent, Inc. (NUVL)
CIK: 0001861560
Period of Report: 2024-03-27

Reporting Person: Hack Andrew A. F. (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-03-27	Class A Common Stock	S	88205	$76.8807	Disposed	3489062	Indirect
2024-03-27	Class A Common Stock	S	791795	$72.31	Disposed	2697267	Indirect

Footnotes

F1: Represents shares of Class A Common Stock held directly by Bain Capital Life Sciences Fund II, L.P. ("BCLS Fund II"), BCIP Life Sciences Associates, LP ("BCIPLS") and BCLS II Investco, LP ("BCLS II Investco" and, together with BCLS Fund II and BCIPLS, the "Bain Capital Life Sciences Entities").

F2: Bain Capital Life Sciences Investors, LLC ("BCLSI") is the ultimate general partner of each of BCLS Fund II and BCLS II Investco and governs the investment strategy and decision-making process with respect to investments held by BCIPLS. Dr. Hack is a Partner of BCLSI. By virtue of the relationships described in this footnote, Dr. Hack may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. Dr. Hack disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.46 to $77.44, inclusive. The reporting person undertakes to provide to Nuvalent, Inc., any security holder of Nuvalent, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.